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Abstract. The present study aimed to identify differences in 
protein expression in cases of endometrioid endometrial cancer 
(EEC) with and without coexisting adenomyosis uteri (AM), 
and to evaluate the histopathological and prognostic distinc-
tions. The total cohort included 22 patients in Group A (patients 
with concomitant AM and EEC) and 35 patients in Group B 
(patients affected only by EEC). Evaluation of the following 
factors was performed: Tumour grade, International Federa-
tion of Gynaecology and Obstetrics (FIGO) stage, survival, 
and expression of estrogen receptor β (ERβ), glycodelin and 
inhibin βB. Group A (AM and EEC) was associated with a 
lower tumour grade (G1, 90.9 vs. 45.7%; P=0.001) and a lower 
FIGO stage (FIGO stage I, 100 vs. 80%; P=0.002) compared 
with Group B (EEC only). In the survival analysis, Group A 
was associated with a significantly higher 5‑year survival rate 
(95 vs. 82%; P=0.024) than Group B. In addition, the expres-
sion of ERβ in Group A was significantly higher (P<0.001), 
whereas the expression of glycodelin is significantly lower 
(P=0.028), compared with Group B. The results of the present 
study indicate that the presence of AM in cases of EEC may 
be a positive prognostic factor.
Introduction
Endometrial cancer (EC) is the most commonly occurring 
malignant neoplasm of the female reproductive tract in 
developed countries (1). Typically, EC is confined to the uterus 
and is characterized by a good prognosis, with an overall 
5-year survival rate of 75-80% (2). Endometrial endometrioid 
cancer (EEC), a histological subtype of EC, represents 80% of 
all cases of EC (2).
Adenomyosis uteri (AM) is defined by the presence of 
endometrial mucosa within the myometrium. In hysterectomy 
specimens obtained during the treatment of EEC, AM may be 
found in 16-42% (3-6). A more favorable prognosis and a lower 
histopathological grade in cases EEC with coexisting AM has 
been reported in a number of studies (3,4,7,8). However the 
significance of the presence of AM in cases of EEC remains 
unclear. Despite early predictions, the collective evidence 
suggests that estrogen receptor β (ERβ) serves an important 
role in normal endometrial tissue (9-11) and also in most, if 
not all, benign and malignant endometrial diseases (12-14). 
In ectopic endometrial lesions and AM, it has been reported 
that high levels of ERβ expression, 100-times higher than 
that in eutopic endometrium, may be detected (15). In EEC, 
it has been reported that ERβ mRNA and protein levels are 
decreased compared with adjacent normal endometrium or 
normal proliferative endometrium from healthy premeno-
pausal women (16,17). However, a potential oncogenic role of 
ERβ has also been proposed in other reports, which showed an 
upregulation of the ERβ5 transcript in high-grade EEC (18,19). 
In summary, ERβ appears to play a dual role: As a tumour 
suppressor in healthy endometrium, and as a potential tumour 
promoter in high-grade EC cells that have lost other receptor 
subtypes (12).
The present study aimed to identify the differences in the 
expression of several proteins, including ERβ, in cases of EEC 
with and without AM, and to evaluate the potential histopatho-
logical and prognostic distinctions between these two groups.
Patients and methods
Patients and specimen characteristics. The present retrospec-
tive observational cohort study included 57 patients with 
EEC, whose records were obtained from the archives of the 
Department of Obstetrics and Gynaecology, Ludwig-Maxi-
milian University of Munich (Munich, Germany). Group 
A consisted of 22 patients with coexistent EEC and AM. 
Coexistence of adenomyosis uteri and endometrial 
cancer is associated with an improved prognosis 
compared with endometrial cancer only
LINDA HERTLEIN,  JOHANNA RATH,  CHRISTINE ZEDER-GÖSS,  SOPHIE FÜRST,  DANIELA BAYER,  
FABIAN TRILLSCH,  SVEN MAHNER,  ALEXANDER BURGES  and  UDO JESCHKE
Department of Obstetrics and Gynecology, Ludwig-Maximilian University of Munich, D-81377 Munich, Germany
Received January 24, 2017;  Accepted May 11, 2017
DOI: 10.3892/ol.2017.6592
Correspondence to: Dr Linda Hertlein, Department of Obstetrics 
and Gynecology, Ludwig-Maximilian University of Munich, 
Campus Großhadern, Marchioninistraße 15, D-81377 Munich, 
Germany
E-mail: linda.hertlein@med.uni-muenchen.de
Abbreviations: AM, adenomyosis uteri; EC, endometrial cancer; 
EEC, endometrioid endometrial cancer; ERβ, estrogen receptor β; 
IRS, immunoreactivity score
Key words: endometrioid endometrial cancer, adenomyosis uteri, 
estrogen receptor β, glycodelin, inhibin βB
HERTLEIN et al:  PROGNOSIS OF COEXISTENT ADENOMYOSIS UTERI AND ENDOMETRIAL CANCER 3303
Group B comprised 35 patients with EEC alone. Patients had 
undergone surgical resection of EEC between January 1990 
and December 2002. The patients' former tumour stages were 
corrected to the updated FIGO classification from 2010 (20).
Study design. Patients were recruited between 1990 and 2002 
as described; follow-up continued until December 2015. Clin-
ical and follow-up data were retrieved retrospectively from 
patient charts and from the Munich Cancer Registry (Munich, 
Germany). The overall mean follow-up time of the cohort 
was 8 years (range, 4-15 years). The outcomes assessed were 
overall survival time and progression free survival. Overall 
survival is defined as the number of months between the 
patient's initial diagnosis with endometrial carcinoma until 
the last follow up or mortality. Progression free survival is 
defined by the number of months between the initial diagnosis 
and when the patient developed either a relapse or further 
progression of the disease, including lymph node involvement 
or metastasis.
Ethical approval. All patient data were fully anonymized, 
and the study was performed according to the standards 
set in the Declaration of Helsinki, 1975. All tumour tissue 
used in the study was leftover material that had initially been 
collected for histopathological diagnostic assessments. All 
diagnostic procedures had already been fully completed when 
samples were retrieved for the study. The present study was 
approved by the Ethics Committee of the Ludwig-Maximilian 
University of Munich (approval no. 449-14). Investigators 
were blinded to the patients' clinical information during 
experimental analysis.
Assay methods. Formalin-fixed, paraffin-embedded tissue 
sections were stored at room temperature. Tumour tissues and 
tissues with AM were selected from hematoxylin-stained whole 
uterus slides. Sections with a thickness of 2 µm of tumour or 
AM positive tissue were prepared and used for the staining. 
Slides were dewaxed in xylol and rehydrated in a descending 
series of alcohol concentrations. The immunohistochemical 
staining of the paraffin‑embedded tissues for glycodelin (in 
Group B) and inhibin βB was detected with the avidin-biotin 
complex method described by Kricka and Wild (21) using the 
mouse VECTASTAIN Elite ABC kit (Vector Laboratories, 
Inc., Burlingame, CA, USA). For the detection of glycodelin 
(in Group A) and ERβ1, the ZytoChem Plus HRP Polymer 
kit (Zytomed Systems GmbH, Berlin, Germany) was used, 
according to the manufacturer's protocol. The primary anti-
bodies are described in Table I, and were incubated with the 
tissue sections for 16 h at 4˚C, prior to detection with the 
aforementioned methods.
Immunoreactivity was quantified with Remmele's 
semi-quantitative immunoreactivity score (IRS) (22) by two 
independent observers by consensus. This scoring method 
quantifies immunoreactivity by multiplication of the optical 
staining intensity score (0, none; 1, weak; 2, moderate; or 3, 
strong) with a score representing the percentage of positively 
stained cells (0, no staining; 1, ≤10% of cells; 2, 11‑50% of 
cells; 3, 51‑80% of cells; or 4, ≥81% of cells), resulting in the 
overall IRS, which can be subdivided as follows: 0-2, nega-
tive; 3-4, weak-positive; 6-8, moderate-positive; and 9-12, 
strong-positive.
Statistical analysis. The IBM statistical package SPSS 
(version 23; IBM, Armonk, NY, USA) was used to test data 
for statistical significance. A Mann-Whitney U-Test was 
performed for analyses of differences in staining results 
and Spearman's rank correlation analysis was performed for 
correlation analyses. Survival times were compared by using 
Kaplan-Meier estimates, and the differences in the patients' 
overall survival rates were tested for significance by using the 
log‑rank test. Data were considered to be statistically signifi-
cantly different where P<0.05.
Results
General patient features. The patients in Group A (AM and 
EEC) and Group B (EEC only) were similar in age at time of 
EEC diagnosis (mean age, 63.9 vs. 63.2 years, respectively). 
With regard to the prevalence of diabetes, hypertension or 
obesity in the patients' medical histories, there were no signifi-
cance differences between the groups. The clinicopathological 
characteristics and follow-up data of all included patients are 
reported in detail in Table II.
AM is associated with lower FIGO stage in EEC. In the 
current cohort, the surgical FIGO stage differed signifi-
cantly between the two groups. In Group A (AM and EEC), 
22/22 patients (100%) were assigned to FIGO stage I, 
compared with 28/35 patients (80%) in Group B (EEC 
only; P=0.002). Notably, 86.4% (19/22 patients) of Group A 
and 51.4% (18/35 patients) of Group B were categorized as 
stage IA. In Group B, 3/35 patients (8.6%) were assigned to 
Table I. Primary antibodies used in the study.
Primary      
antibody Host Clone Cat. no. Supplier Dilution
Estrogen Mouse (IgG2a) PPG5/10 M7292 Dako; Agilent Technologies 1:200 in Dako
receptor β 1    GmbH, Waldbronn, Germany antibody diluent
Glycodelin Mouse (IgG1κ) 6F2 116-0646 Zytomed Systems GmbH,  1:4,000 in PBS
    Berlin, Germany
Inhibin βB Mouse (IgG2a) C5 MCA1661 Serotec; Bio-Rad Laboratories,  1:70 in Dako
    Inc., Hercules, CA, USA antibody diluent
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FIGO stage II, and 4/35 patients (11.4%) were assigned to 
FIGO stage III.
AM is associated with a lower grade in EEC. With regard to 
the prevalence of lymphatic or vascular invasion, no signifi-
cant differences between the two groups could be identified. 
Regarding tumour grade, a significant difference was identi-
fied between Group A and Group B (G1, 90.9 vs. 45.7%; G2, 
4.5 vs. 51.4%; G3, 0 vs. 2.9%, respectively; P=0.001; Fig. 1). 
Thus, higher tumour grades, indicating poor differentiation of 
the tumour cells, were more common in the patients without 
AM.
AM is associated with increased survival time in patients 
with EEC. The survival curves of the patients in Groups A 
and B are shown in Fig. 2. The 5-year overall survival rate of 
Group A was 95%, which was significantly higher than that 
of Group B (82%; P=0.024). The survival rate after 10 years 
remained the same for Group A, whereas the 10-year survival 
rate of Group B decreased to 72%. The mean overall survival 
Table II. General features, histological features and follow-up data of the patients in the two study groups.
Characteristic All patients (n=57) Group Aa (n=22) Group Bb (n=35) P-value
Age at diagnosis, years    0.987
  Mean 63.5 63.9 63.2
  Range 36-83 52-82 36-83 
Obesity, n (%)    0.583
  Yes 18 (31.6) 6 (27.3) 12 (34.3) 
  No 39 (68.4) 16 (72.7) 23 (65.7) 
Diabetes, n (%)    0.946
  Yes 8 (14.0) 3 (13.6) 5 (14.3) 
  No 49 (86.0) 19 (86.4) 30 (85.7) 
Hypertension, n (%)    0.703
  Yes 19 (33.3) 8 (36.4) 11 (31.4) 
  No 38 (66.7) 14 (63.6) 24 (68.6) 
FIGO stage, n (%)     0.002
  I 50 (87.7) 22 (100) 28 (80.0) 
    IA 37 (64.9) 19 (86.4) 18 (51.4) 
    IB 13 (22.8) 3 (13.6) 10 (28.6) 
  II 3 (5.3) 0 (0.0) 3 (8.6) 
  III 4 (7.0) 0 (0.0) 4 (11.4) 
  IV 0 (0.0) 0 (0.0) 0 (0.0) 
Lymph node metastasis, n (%) 2 (3.5) 1 (4.5) 1 (2.9) 
Distant metastasis, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 
Grade, n (%)     0.001
  1 36 (63.2) 20 (90.9) 16 (45.7) 
  2 19 (33.3) 1 (4.5) 18 (51.4) 
  3 1 (1.8) 0 (0.0) 1 (2.9) 
Lymphatic invasion, n (%)     0.849
  Yes 3 (5.3) 1 (4.5) 2 (5.7) 
  No 54 (94.7) 21 (95.5) 33 (94.3) 
Vascular invasion, n (%)     0.428
  Yes 1 (1.8) 0 (0.0) 1 (2.9) 
  No 56 (98.2) 22 (100) 34 (97.1) 
Follow-up duration, years    
  Mean - 8.9 7.8 
  Range - 4-14 5-14 
Mortality during follow-up, n (%) 10 (17.5) 2 (9.1) 8 (22.9) 
No follow-up, n (%) 2 (5.7) 0 (0.0) 2 (5.7) 
aAM and EEC; bEEC only. AM, adenomyosis uteri; EEC, endometrioid endometrial cancer; FIGO, International Federation of Gynaecology 
and Obstetrics.
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time was higher in Group A than in Group B (159 months 
(13.25 years) vs. 142 months (11.8 years), respectively). In 
summary, patients with AM and EEC (Group A) had a signifi-
cantly increased mean overall survival times than patients 
with EEC alone (Group B; P=0.024).
AM is associated with increased expression of ERβ and 
decreased expression of glycodelin in EEC. Table III summa-
rizes the results of the different protein expression analyses. 
When comparing the percentage of cases with an IRS >2 for 
ERβ, a significant difference was identified between the two 
groups (P<0.001): In Group B, ERβ expression was detected 
in 6/35 cases (17.1%), and only 1 case (2.9%) was assigned an 
IRS >2 (Fig. 3); whereas, in Group A, 14/20 cases assessed 
for ERβ expression (70%) exhibited expression of ERβ, with 
6 cases (30%) assigned an IRS >2 (Fig. 4). Therefore, the 
presence of AM in cases of EEC is associated with higher 
expression of ERβ than that in cases of EEC alone. In Group A, 
the prevalence of glycodelin expression with an IRS >2 was 
significantly lower (P=0.028; Fig. 5) than that in Group B 
(Fig. 6; Table III). With regard to the prevalence of inhibin βB 
expression (data not shown), no significant differences between 
the two groups were identified (P=0.077).
Discussion
The majority of cases of EC (80%) are of the endometrioid 
subtype (EEC) (2). This Type I EC is estrogen-dependent, is 
typically well-differentiated, and is characterized by a good 
prognosis in general. By contrast, Type II EC is estrogen-inde-
pendent, predominantly comprises the serous and clear cell 
histological subtypes, and has a worse prognosis (23-26).
AM is a benign disease characterized by the presence 
of endometrial mucosa within the myometrium. It is a 
hormone-dependent disease and typically regresses subsequent 
to menopause. In postmenopausal women with EEC, there is a 
higher prevalence of AM and myoma uteri than in patients of 
the same age with uterine prolapse (27). Certain studies have 
reported a more favorable prognosis and a lower histopatho-
logical grade in cases of EEC with coexisting AM (3,4,7,8).
Regarding the tumour stage, all 22 patients in Group A 
(AM and EEC; 100%) vs. only 28/35 patients (80%) in 
Group B (EEC only) were assigned to FIGO stage I (P=0.02). 
Additionally, a higher percentage of patients in Group A, 
compared with Group B, were assigned to FIGO stage IA 
(86.4 vs. 51.4%). These findings are in accord with the find-
ings of studies by Musa et al (28) and Gizzo et al (7), which 
Table III. Expression of the different proteins in the different groups.
Protein All patients  Group Aa  Group Bb  P-value
Estrogen receptor β (IRS >2), n (%)     <0.001
  Yes  7 (12.7) 6 (30.0) 1 (2.9) 
  No 48 (87.3) 14 (70.0) 34 (97.1) 
Glycodelin (IRS >2), n (%)     0.028
  Yes 38 (86.4) 15 (78.9) 23 (92.0) 
  No 6 (13.6) 4 (21.1) 2 (8.0) 
Inhibin βB (IRS >2), n (%)    0.077
  Yes 34 (94.4) 14 (93.3) 20 (95.2) 
  No 2 (5.5) 1 (6.7) 1 (4.8) 
aAM and EEC; bEEC only. AM, adenomyosis uteri; EEC, endometrioid endometrial cancer; IRS, immunoreactivity score.
Figure 1. Association between grade and presence of adenomyosis uteri in 
patients with endometrioid endometrial cancer.
Figure 2. Survival curves of the endometrioid endometrial cancer patients 
with and without adenomyosis uteri (P=0.024).
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reported that concurrent AM and EEC was associated with a 
lower tumour grade, with <50% myometrial invasion, and with 
the absence of lymphovascular space involvement and lymph 
node metastasis. Furthermore, the lower histopathological 
grade (G1, 90.9 vs. 45.7%, respectively) in Group A (with AM) 
vs. Group B (without AM) observed in the present study was 
consistent with the report by Koshiyama et al (8). Thus, the 
present study confirmed that patients with coexisting AM and 
EEC tend to have a lower tumour stage and a higher differen-
tiation grade. One possible explanation for this finding could 
be that there is an adhesion mechanism between AM foci and 
cancer cells; these adhesions may prevent cancer cells from 
invading deeper in the myometrium (29-31). Regarding the 
survival data, patients with EEC and coexistent AM showed 
significantly more favorable outcomes than those with EEC 
alone.
Although previous studies have investigated ERβ, 
glycodelin and inhibin βB in cases of AM and EEC (31-35), 
to the best of our knowledge, the present study is the first in 
which these factors were measured and compared with one 
other in a single study. Regarding the expression of ERβ, 
Group A (AM and EEC) showed a significantly increased 
prevalence compared with Group B (EEC). This result may 
be explained by the increased expression of ERβ that has been 
shown to be present in AM (15). The decreased expression 
of ERβ in patients with EEC alone was also consistent with 
previous studies (16,17).
Glycodelin, also known as a progestogen-associated endo-
metrial protein, is a glycoprotein that has immunosuppressive 
capacity, and is predominantly produced in reproductive 
tissues (36). In a former study by our group, intermediate 
and high expression levels of glycodelin were associated with 
a prolonged survival time in patients with EC (33). Notably, 
in the current study, the prevalence of glycodelin expres-
sion in Group A (AM and EEC) was significantly decreased 
compared with that in Group B (EEC; P=0.028). This can 
be explained because women with endometriosis exhibited a 
>50-fold downregulation of glycodelin in endometrial tissue 
compared to normal controls during the window of implanta-
tion (37). This decreased glycodelin expression also seemed to 
persist during the carcinogenesis of EC in the present study. 
In this context, women with AM and EEC appear to have a 
survival advantage, which could be explained by the angio-
genic role of glycodelin during tumorigenesis; Song et al (38) 
Figure 3. ERβ expression in Group B (patients with endometrioid endometrial 
cancer only). Representative photomicrographs of ERβ immunohistochem-
ical staining are shown (immunoreactivity score, 0). ERβ, estrogen receptor β.
Figure 4. ERβ expression in Group A (patients with endometrioid endome-
trial cancer and adenomyosis uteri). Representative microphotographs of 
ERβ immunohistochemical staining are shown (immunoreactivity score, 2). 
ERβ, estrogen receptor β.
Figure 5. Glycodelin expression in Group A (patients with endometrioid endo-
metrial cancer and adenomyosis uteri). Representative microphotographs of 
glycodelin immunohistochemical staining are shown (immunoreactivity 
score, 4).
Figure 6. Glycodelin expression in Group B (patients with endometrioid 
endometrial cancer only). Representative microphotographs of glycodelin 
immunohistochemical staining are shown (immunoreactivity score, 6).
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found that a synthetic peptide derived from the sequence of 
glycodelin may serve an important role in neovascularization 
during embryogenesis and tumour development. It is notable 
that the inverse association between the presence of AM and 
the expression of glycodelin in EEC has only been identified 
in specimens that were stained with an antibody raised against 
a peptide sequence of glycodelin, and not in those that were 
stained with anti-glycodelin A antibody, which is specific 
to a particular glycosylated form of glycodelin (39-41). The 
measurement of glycodelin or ERβ was previously described 
in endometrial tissue (42,43). However, no correlation between 
these two parameters has been described.
Inhibins are heterodimers consisting of an α subunit and a 
β subunit, and they belong to the transforming growth factor 
β cytokine family (44). The α subunit can dimerize with either 
βA or βB to form inhibin A (α-βA) or B (α-βB) (45,46). In a 
previous study by our group, hyperplastic endometrial tissue 
was found to exhibit more intense staining for inhibins, partic-
ularly inhibin βA and βB, compared with EC. The presence 
of inhibin βA and βB suggests that they have an important 
function in endometrial pathogenesis and in endometrial 
carcinogenesis (34). For inhibin βB, more intense labelling 
was noted in atypical hyperplasia compared with EC (34). 
Thus, the present study investigated the differences in the 
expression of inhibin βB between the two groups. However, no 
significant differences were observed. In adenosquamous EC, 
the absence of the expression of inhibin βB and ERβ indicates 
the malignancy of these tumors (32).
One limitation of the present study was the variation in 
immunostaining in each specimen due to varying expression 
levels in different regions of the tumour. Other molecular 
methods for determining expression levels, such as western 
blotting, would be desirable to verify the results. However, as 
the present study utilized formalin‑fixed, paraffin‑embedded 
tissue specimens, this was not possible.
In conclusion, in cases of EEC, the presence of AM is 
associated with a lower FIGO stage, lower tumour grade and 
an increased survival rate. The expression of ERβ was more 
prevalent in cases of AM and EEC than in cases of EEC alone, 
whereas glycodelin expression was less prevalent when AM 
was present. Future research should focus on the influence 
of estrogen on the AM and EEC cases, and on prevention 
strategies in the development of EEC.
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